Compare
Jazz Pharmaceuticals vs Johnson & Johnson (JAZZ vs JNJ)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Jazz Pharmaceuticals (JAZZ) returned +71.1% and Johnson & Johnson (JNJ) +48.5%; so far this year the figures are +38.1% and +33.5%.
Johnson & Johnson is the larger company by market value, about 44.1 times the size of Jazz Pharmaceuticals.
On trailing earnings, JAZZ trades at 76.5 times and JNJ at 41.9 times.
Revenue grew +13.5% at JAZZ and +7.8% at JNJ over the last year.
JAZZ pays no dividend. JNJ yields 1.91%.
Data as of the latest close. Not investment advice.
Relative performance
| JAZZ | JNJ | |
|---|---|---|
| Price | $234.76 | $276.22 |
| 1-day | +3.27% | +1.43% |
| YTD | +38.09% | +33.47% |
| 1 year | +71.08% | +48.51% |
| 3 years | +84.36% | +85.77% |
| Market cap | $15.1B | $665.0B |
| P/E | 76.5 | 41.9 |
| P/S | 3.19 | 6.69 |
| P/B | 3.59 | 8.16 |
| Revenue growth | +13.50% | +7.80% |
| EPS growth | — | -36.40% |
| Gross margin % | — | 67.6 |
| Net margin % | 4.4 | 16.2 |
| ROE % | 4.9 | 19.7 |
| Debt / equity | 1.33 | 0.55 |
| FCF yield % | 10.8 | 3.1 |
| Dividend yield % | — | 1.91 |
| Beta | 0.53 | -0.09 |
| RSI (14) | 60.5 | 59.4 |
| Technical rating |